Erste Asset Management Gmb H Macrogenics Inc Transaction History

Erste Asset Management Gmb H

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Nov 26, 2024	SELL	$2.25 - $9.99 $25,650 - $113,886	-11,400 Closed	0 $0
Q1 2022 Nov 22, 2024	SELL	$8.12 - $16.9 $146,160 - $304,200	-18,000 Closed	0 $0
Q4 2021 Nov 22, 2024	BUY	$15.91 - $21.88 $286,380 - $393,840	18,000 New	18,000 $286 Million
Q4 2020 Nov 22, 2024	BUY	$19.41 - $26.0 $349,380 - $468,000	18,000 New	18,000 $411 Million
Q3 2019 Nov 22, 2024	SELL	$12.44 - $17.48 $141,816 - $199,272	-11,400 Closed	0 $0
Q1 2019 Nov 22, 2024	BUY	$11.11 - $25.6 $126,654 - $291,840	11,400 New	11,400 $200 Million
Q4 2018 Nov 26, 2024	BUY	$11.75 - $21.42 $133,950 - $244,188	11,400 New	11,400 $144 Million

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $199M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Erste Asset Management Gmb H with notifications on news.